Literature DB >> 11180041

Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.

M Nakajima1, J T Kwon, N Tanaka, T Zenta, Y Yamamoto, H Yamamoto, H Yamazaki, T Yamamoto, Y Kuroiwa, T Yokoi.   

Abstract

BACKGROUND: Nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. Previously, we found that the CYP2A6 gene was deleted homozygously in one subject who was deficient in cotinine formation from nicotine.
OBJECTIVE: Our objective was to clarify the relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism.
METHODS: Nicotine was administered to 92 healthy Japanese subjects in the form of 1 piece of nicotine gum to investigate the potency of nicotine metabolism. The cotinine-nicotine ratio of the plasma concentration 2 hours after chewing was calculated as an index of nicotine metabolism. The genotypes of CYP2A6 gene, CYP2A6*1A, CYP2A6*1B, CYP2A6*2, CYP2A6*3, CYP2A6*4, and CYP2A6*5, were determined with polymerase chain reaction-restriction fragment length polymorphism.
RESULTS: A large interindividual difference in nicotine metabolism was observed. Allele frequencies of CYP2A6*1A, CYP2A6*1B, and CYP2A6*4 were 42.4%, 37.5%, and 20.1%, respectively. The CYP2A6*2, CYP2A6*3, and CYP2A6*5 alleles were not found. Three subjects genotyped as CYP2A6*4/CYP2A6*4 were completely deficient in cotinine formation. The heterozygotes of the CYP2A6*4 allele tend to show lower capacities for cotinine formation. The subjects with CYP2A6*1A/CYP2A6*1B appeared to have higher capacities of cotinine formation than subjects with CYP2A6*1A/CYP2A6*1A, although the difference was not significant. The probit plot of the cotinine-nicotine ratio was not linear; this possibly indicated the existence of a novel mutation in the CYP2A6 gene genotyped as CYP2A6*1B/CYP2A6*4.
CONCLUSIONS: The relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans was proved.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180041     DOI: 10.1067/mcp.2001.112688

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users.

Authors:  Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder
Journal:  Nicotine Tob Res       Date:  2015-05-14       Impact factor: 4.244

3.  CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.

Authors:  Yu-liang Liu; Yu Xu; Fan Li; Hong Chen; Shu-liang Guo
Journal:  Tumour Biol       Date:  2013-05-07

Review 4.  Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.

Authors:  Michael Mamoun; Andrew W Bergen; Jennifer Shieh; Anna Wiggins; Arthur L Brody
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

5.  Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.

Authors:  Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn E Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-06       Impact factor: 4.254

6.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

7.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

8.  Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.

Authors:  Hiroshi Yamazaki; Kana Horiuchi; Ryohji Takano; Taku Nagano; Makiko Shimizu; Masato Kitajima; Norie Murayama; Fumiaki Shono
Journal:  Int J Environ Res Public Health       Date:  2010-09-01       Impact factor: 3.390

9.  CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking.

Authors:  Wiratchanee Mahavorasirikul; Wichittra Tassaneeyakul; Soisagwan Satarug; Ronnatrai Reungweerayut; Chacrin Na-Bangchang; Kesara Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

10.  Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.

Authors:  Papichaya Phompradit; Poonuch Muhamad; Anurak Cheoymang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2014-06-02       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.